Enregistrez cette offre et organisez votre recherche
Créez un compte gratuit pour enregistrer des offres d'emploi, créer des alertes et revenir à cette liste depuis votre tableau de bord.
En continuant, vous acceptez nos Conditions d’utilisation & Politique de confidentialité.
Organisation/Company CNRS Department Institut des Neurosciences Cellulaires et Intégratives Research Field Neurosciences Biological sciences Researcher Profile First Stage Researcher (R1) Application Deadline 25 Nov 2026 - 23:59 (UTC) Country France Type of Contract Temporary Job Status Full-time Hours Per Week 35 Offer Starting Date 1 Jan 2027 Is the job funded through the EU Research Framework Programme? Not funded by a EU programme Is the Job related to staff position within a Research Infrastructure? No
Offer Description
The successful candidate will join the Institute of Cellular and Integrative Neurosciences (INCI) in Strasbourg, a CNRS research institute employing approximately 140 people.
The PhD student will work within the “Opioid System, Nociception and Pain” research team, comprising nine members, including one postdoctoral researcher and two PhD students.
Our institute offers a stimulating, friendly, and international research environment.
INCI provides access to several core facilities, including the Small Molecule Mass Spectrometry Platform (SMPMS), molecular biology facilities, and a functional imaging platform.
The hosting team has strong international recognition in neuroscience, particularly in neuroinflammation, neuropathic pain, and opioid-based treatments.
INCI is located on the University of Strasbourg's Esplanade campus (Green Campus), close to the city center, with convenient access to public transportation and student dining facilities.
The PhD project will be affiliated with Doctoral School 414 – Life and Health Sciences (ED414) at the University of Strasbourg.
Impact of Systemic Inflammation on Glial Cell-Mediated Monoamine Metabolism in the Central Nervous System and Its Consequences for Nociception
Project Description
Sepsis, defined as a dysregulated systemic response to severe infection, accounts for approximately 20% of deaths worldwide. This condition is frequently associated with neurological complications, hyperalgesia, and sepsis-associated encephalopathy (SAE), which affects up to 70% of patients. The resulting neuroinflammation leads to the activation of glial cells, particularly microglia and astrocytes.
Glial activation is associated with increased expression of the aryl hydrocarbon receptor (AhR), a transcription factor involved in the regulation of numerous metabolic enzymes, including UDP-glucuronosyltransferases (UGTs). These enzymes catalyze the glucuronidation of a wide range of xenobiotics as well as endogenous compounds.
Among these enzymes, UGT1A6a has been reported to glucuronidate serotonin in vitro, a neurotransmitter strongly affected during sepsis. The same enzyme is also involved in morphine glucuronidation.
Hypothesis
We hypothesize that, during sepsis, glial activation induces the AhR–UGT1A6a signaling pathway in astrocytes, leading to increased glucuronidation of key neurotransmitters, such as serotonin, thereby contributing to neurological dysfunction and sepsis-associated hyperalgesia.
Inhibition of AhR and/or UGT1A6a in astrocytes could therefore reduce this abnormal glucuronidation, restore neurotransmitter levels, and potentially improve neurological recovery and alleviate hyperalgesia.
Proof of Concept
- 1. Glial cells are capable of glucuronidating morphine in vitro.
- 2. LPS increases morphine glucuronidation by glial cells both in vitro and in vivo, an effect inhibited by SR1, an AhR antagonist.
- 3. LPS specifically increases UGT1A6 expression in glial cells.
- 4. Both global AhR knockout and astrocyte-specific AhR deletion reduce morphine metabolism and enhance its analgesic effect.
- 5. The brains of LPS-treated mice contain substantial amounts of serotonin glucuronide.
- 6. shRNA-mediated knockdown of UGT1A6a in primary astrocyte cultures significantly reduces morphine metabolism.
Together, these findings suggest the existence of a functional neuroinflammation–AhR–UGT1A6a–glucuronidation axis in glial cells, potentially affecting not only xenobiotic metabolism but also the metabolism of endogenous neurotransmitters.
Objectives
- 1. Identify neurotransmitters glucuronidated by glial cells in vitro under basal and LPS-induced inflammatory conditions, focusing particularly on serotonin, adrenaline, noradrenaline, and dopamine.
- 2. Identify neurotransmitters and other endogenous metabolites glucuronidated in vivo during sepsis, using a differential metabolomics approach in the brains of control and LPS-treated mice.
- 3. Determine the involvement of AhR and UGT1A6a in neurotransmitter glucuronidation, using pharmacological approaches targeting AhR (SR1) and genetic models involving AhR or UGT1A6a deletion.
- 4. Investigate the consequences of astrocyte-specific deletion of AhR or UGT1A6a on neurotransmitter metabolism, neurotransmission, and pain, usin